PhoreMost
PrivateLast Round
Series B
Extension
Sep 10, 2024
Total Funding Raised
$78.17M
Company Overview
PhoreMost operates in Healthcare & Life Sciences and is based in Cambridge. Its latest recorded funding round was a Series B Extension round in September 2024.
PhoreMost is a biotechnology company that specializes in drug target identification and discovery services using its proprietary SITESEEKER® and PROTEINi® platforms to address undruggable targets in oncology and other diseases.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
PhoreMost Comparables
Compare PhoreMost with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| PharmEnable Therapeutics | 82% | |
| Frontier Medicines | 81% | |
| SyntheX | 80% |
For institutional investors. Book with your work email.
PhoreMost Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Sep 10, 2024 | ||||
| Series B | Mar 23, 2021 | ||||
| Grant | Apr 27, 2018 | ||||
| Grant | Jun 23, 2017 | ||||
| Grant | May 21, 2015 | ||||
Seed | Apr 7, 2015 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
PhoreMost Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Amadeus Capital Partners | Grant, Series B Extension, Series B, Seed |
| BGF | Series B Extension, Series B |
| o2h ventures | Series B, Seed |
| Morningside Ventures | Grant, Series B |
| Meltwind Advisory | Series B Extension, Series B |
| Innovate UK | Grant |
| Cambridge Enterprise | Grant, Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 28, 2025
Dr. Adam Gilbert joins the Scientific Advisory Board.
- May 7, 2025
Stephen Dilly joins as Non-Executive Director.
For institutional investors. Book with your work email.
PhoreMost Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about PhoreMost's valuation, stock price, and market status.
Is PhoreMost a public or private company?
PhoreMost is a private company.
What is the current stock price of PhoreMost?
PhoreMost is a private company, so its shares have no public market price. Caplight tracks PhoreMost's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is PhoreMost worth (valuation)?
Valuation information for PhoreMost is not publicly available.
Can I buy PhoreMost stock?
PhoreMost shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was PhoreMost's last funding round?
PhoreMost's most recent funding round was Series B Extension on September 10, 2024.
Who are the main investors in PhoreMost?
Key investors in PhoreMost include Amadeus Capital Partners, BGF, Innovate UK, Parkwalk Advisors.
Will PhoreMost IPO soon?
No public IPO plans have been announced for PhoreMost.
How can I track PhoreMost secondary market activity?
Caplight tracks bids, offers, and trades in PhoreMost's shares on secondary markets.